BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 27,000 shares of the stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00. Following the transaction, the chief executive officer directly owned 314,209 shares in the company, valued at approximately $31,009,286.21. This represents a 7.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.

BioNTech Stock Performance

BNTX traded up $0.56 during trading on Monday, hitting $99.08. The stock had a trading volume of 777,945 shares, compared to its average volume of 1,094,445. The firm has a market cap of $25.06 billion, a PE ratio of -12.65 and a beta of 1.29. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $98.17 and a 200-day simple moving average of $94.74.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter last year, the company earned ($1.60) earnings per share. The firm’s revenue was down 59.5% on a year-over-year basis. Analysts expect that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently added to or reduced their stakes in the company. Flossbach Von Storch SE acquired a new stake in BioNTech during the second quarter valued at approximately $207,142,000. BNP Paribas Financial Markets increased its position in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. First Trust Advisors LP raised its holdings in BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after purchasing an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in BioNTech during the 2nd quarter worth about $39,385,000. Finally, SEB Asset Management AB acquired a new position in BioNTech during the 1st quarter valued at about $17,804,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BNTX has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Morgan Stanley cut their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a research note on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.